Jefferies Financial Group Inc. bought a new stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the fourth quarter, HoldingsChannel.com reports. The fund bought 10,522 shares of the biopharmaceutical company’s stock, valued at approximately $3,930,000. Regeneron Pharmaceuticals accounts for approximately 0.5% of Jefferies Financial Group Inc.’s investment portfolio, making the stock its 14th biggest position.
Other institutional investors have also added to or reduced their stakes in the company. Whittier Trust Co. lifted its stake in Regeneron Pharmaceuticals by 195.7% in the fourth quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 45 shares during the last quarter. Rehmann Capital Advisory Group lifted its stake in shares of Regeneron Pharmaceuticals by 1,700.0% during the 3rd quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 68 shares during the last quarter. AdvisorNet Financial Inc lifted its stake in shares of Regeneron Pharmaceuticals by 208.0% during the 4th quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 52 shares during the last quarter. Captrust Financial Advisors acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $30,000. Finally, Intercontinental Wealth Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $33,000. 66.87% of the stock is owned by institutional investors and hedge funds.
NASDAQ:REGN traded up $5.08 during mid-day trading on Friday, reaching $412.58. 5,728 shares of the company’s stock were exchanged, compared to its average volume of 729,211. Regeneron Pharmaceuticals Inc has a one year low of $281.89 and a one year high of $442.00. The firm has a market cap of $44.89 billion, a price-to-earnings ratio of 20.81, a P/E/G ratio of 1.68 and a beta of 1.20. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 131,115 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Joseph L. Goldstein sold 1,791 shares of the firm’s stock in a transaction dated Thursday, January 10th. The shares were sold at an average price of $410.00, for a total transaction of $734,310.00. Following the completion of the transaction, the director now directly owns 14,114 shares in the company, valued at $5,786,740. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 134,754 shares of company stock worth $55,439,356. 12.42% of the stock is owned by insiders.
REGN has been the subject of a number of research reports. Guggenheim cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $466.00 to $425.00 in a research note on Friday, February 22nd. TheStreet upgraded shares of Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, January 17th. BidaskClub cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 7th. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 target price for the company in a research note on Thursday, February 7th. Finally, Oppenheimer set a $440.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, December 2nd. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $413.76.
ILLEGAL ACTIVITY NOTICE: This report was posted by WKRB News and is the property of of WKRB News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.wkrb13.com/2019/03/15/jefferies-financial-group-inc-takes-3-93-million-position-in-regeneron-pharmaceuticals-inc-regn.html.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
See Also: How to invest in blue-chip stocks
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.